Svein Dueland
Papers
1
Total Citations
30
H-Index
1
About
Svein Dueland is a pioneering oncologist whose research centers on immunotherapy for high-risk prostate cancer and innovative cancer vaccine strategies. His landmark work includes a first-in-man Phase I/II study of an adjuvant dendritic cell (DC) vaccine for patients with high-risk prostate cancer after radical prostatectomy, published in 2021 with 30 citations. This study demonstrated that personalized DC vaccines could reduce biochemical relapse risk, offering a promising approach to prevent disease progression in patients who might otherwise face noncurative outcomes. Dueland’s contributions have advanced the understanding of how to harness the immune system to target residual cancer cells post-surgery, addressing a critical gap in managing high-risk prostate cancer. His research has significant clinical impact, as it provides a potential pathway to delay or avoid recurrence in a patient population with limited options. By integrating personalized immunotherapy into adjuvant settings, Dueland has helped shape the future of prostate cancer treatment, earning recognition for translating complex immunological concepts into tangible therapeutic benefits.
Research Focus
Key Achievements
Top Papers
- 1